ITEM 7.01. Regulation FD Disclosure

On February 12, 2009, Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) announced that it is the first national clinical laboratory to offer HCV PCR testing using a newly FDA approved assay, the Roche COBAS® AmpliPrep/COBAS® TaqMan® HCV Test. This assay is intended to be used as an aid in managing HCV-infected individuals undergoing antiviral therapy. The assay can reliably measure HCV RNA levels at baseline and at the medical decision time points during treatment predicting response to HCV therapy. Current guidelines and product information for the FDA-approved peginterferons support the importance of measuring HCV RNA levels prior to treatment at baseline, at intervals during treatment to assess antiviral response, and after treatment is completed to assess the efficacy of the treatment.

Exhibits

99.1 Press Release dated February 12, 2009

---